Tezepelumab achieves improvement of severe uncontrolled asthma and rhinosinusitis: Case series
Tezepelumab, a mAb targeting thymic stromal lymphopoietin (TSLP), reduces exacerbations in severe asthma. Four cases in which patients with severe asthma and chronic rhinosinusitis with nasal polyps showed improvements in both conditions after receiving tezepelumab treatment are presented.
Authors
- Kentaro Tanaka (ORCID: https://orcid.org/0000-0001-8645-6436)
- Ayaka Shiota
- Koichi Takagi (ORCID: https://orcid.org/0009-0009-7927-3688)
- Hiromasa Inoue (ORCID: https://orcid.org/0000-0001-8080-3812)
- Shigesato Inoue (ORCID: https://orcid.org/0000-0001-7423-0659)
- Keiko Kan‐o (ORCID: https://orcid.org/0000-0002-7736-588X)
- Yoichi Dotake
- Yumiko Ishii (ORCID: https://orcid.org/0000-0002-7438-3695)
- Hiroaki Ogata (ORCID: https://orcid.org/0000-0002-6932-747X)
Institutions
- Kagoshima University (JP)
- Kyushu University (JP)
- Fukuoka Hospital (JP)
- Fukuoka Higashi Medical Center (JP)
- Tokyo Women's Medical University (JP)
Publication Details
- Journal
- Journal of Allergy and Clinical Immunology Global
- Published
- 2025-03-09
- DOI
- https://doi.org/10.1016/j.jacig.2025.100448
- Citations
- 2
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.33